Conference Program

Satellite-Symposia-Schedule-smaller

 

 

Wednesday, January 14, 2015
All Day Exhibit Setup
10:00 – 19:00 Registration Open
10:00 – 19:00 Poster Setup
18:30 – 18:40 Welcome and Opening Remarks
Mark Hallett (Bethesda, MD, USA)
Alberto Albanese  (Milan, Italy)
18:40 – 19:30 Lifetime Achievement Award Ceremony
19:30 – 21:30 Welcome Reception
Thursday, January 15, 2015
07:00 – 18:30 Registration/Information
07:00 – 08:30 Exhibits
Plenary Session – Mechanisms of Action
Chairs: Giampietro Schiavo (London, UK) and Cynthia Comella (Chicago, IL, USA)
08:30 – 08:45 Welcome and Opening Remarks
Alberto Albanese  (Milan, Italy)
Mark Hallett (Bethesda, MD, USA)
08:45 – 09:45 Keynote Presentation – Cell Biology of the Neuron: Membrane Lipid Dynamics in the Regulation of Synaptic Function
Pietro De Camilli (New Haven, CT, USA)
09:45 – 10:20 Explanation of Timing of Botulinum Neurotoxin (BoNT) Effects, Onset, and Duration and Clinical Ways of Influencing Them
Mark Hallett (Bethesda, MD, USA)
10:20 – 10:50 Break
Plenary Session – Mechanisms of Action
Chairs: Cynthia Comella (Chicago, IL, USA) and Hans Bigalke (Hannover, Germany)
10:50 – 11:25 BoNT Complexes and Their Journey Toward the Nervous System
Andreas Rummel (Hannover, Germany)
11:25 – 12:00 Clinical Comparison of Effects at Neuromuscular Junction and Autonomic Nerves: Similarities and Differences
Markus Naumann (Augsburg, Germany)
12:00 – 13:45 Lunch
12:00 – 14:30 Exhibits
12:00 – 14:30 Poster Session
Participants will break into separate groups for Basic Science, Clinical, Workshop A, Workshop B, Workshop C, and Workshop D sessions.
Parallel Track I (Basic Science)
14:30 – 15:45 Genetics and Evolution
Chair: Eric Johnson (Madison, WI, USA)
 14:30 – 15:00 Genomics and Evolution of Clostridium botulinum and Its Neurotoxins
Michael Peck (Norwich, UK)
 15:00 – 15:30 The Genetic Diversity of Clostridium botulinum and Its Neurotoxins
Karen Hill (Los Alamos, NM, USA)
15:30 – 15:45 Functional Characterization of a Novel Botulinum Neurotoxin F/A Hybrid
Suzanne R. Kalb (Atlanta, GA, USA)
15:45 – 16:15 Break
16:15 – 18:30 Molecular Interactions
Chair:
Thomas Binz (Hannover, Germany)
 16:15 – 16:45 Dissecting the Sophisticated Host-BoNT Interplay in the Gastrointestinal Tract
Rongsheng Jin (Irvine, CA, USA)
 16:45 – 17:15 Disassociation Mechanism of Progenitor Complex of Botulinum Neurotoxin Serotype E
Subramanyam Swaminathan (Upton, NY, USA)
 17:15 – 17:45 Structural Studies of the Binding of the Botulinum Neurotoxins to Protein and Ganglioside Receptors
Pål Stenmark (Stockholm, Sweden)
 17:45 – 18:00 Botulinum Neurotoxin A Complex Exploits Intestinal M Cells to Enter the Host
Yukako Fujinaga (Osaka, Japan)
 18:00 – 18:15 Thioredoxin and Its Reductase Are Present on Synaptic Vesicles and Their Inhibition Prevents the Paralysis Induced by Botulinum Neurotoxins
Marco Pirazzini (Padua, Italy)
 18:15 – 18:30 Nidogens Are Therapeutic Targets for the Prevention of Tetanus
Kinga Bercsenyi (London, UK)
Parallel Track I (Clinical)
14:30 – 16:00 Initial and Subsequent Injections: How Do We Modify the Approach to Optimize Outcomes?
Chair: Diego R. Torres-Russotto (Omaha, NE, USA)
14:30 – 15:00 Cervical Dystonia
Alberto Espay (Cincinnati, OH, USA)
15:00 – 15:30 Writer’s Cramp
Barbara Karp (Bethesda, MD, USA)
15:30 – 16:00 Blepharospasm
Diego R. Torres-Russotto (Omaha, NE, USA)
16:00 – 16:30 Break
16:30 – 18:00 Measuring Outcomes of BoNT Therapy for Dystonia
Chair: Alberto Albanese (Milan, Italy)
16:30 – 17:00 Development of a Rating Scale
Glenn Stebbins (Chicago, IL, USA)
17:00 – 17:30 Focal Dystonia: Rating Scales
Alberto Albanese (Milan, Italy)
17:30 – 18:00 Spasticity: Rating Scales
Allison Brashear (Winston-Salem, NC, USA)
Parallel Track II (Clinical)
14:30 – 16:10 Application of BoNT for the Treatment of Cerebral Palsy
Chair: Ann Tilton (New Orleans, LA, USA)
14:30 – 14:55 Evidence-Based Review of Safety and Efficacy in Cerebral Palsy
Ann Tilton (New Orleans, LA, USA)
14:55 – 15:20 Optimizing Outcomes With Adjunctive Therapy
Anthony Ward (Stoke-on-Trent, UK)
15:20 – 15:45 Special Considerations: Dosing Limits and Reasons that Children Discontinue Therapy
Florian Heinen (Munich, Germany)
15:45 – 16:10 Managing Drooling in Cerebral Palsy
Steffen Berweck (Vogtareuth, Germany)
16:10 – 16:30 Break
16:30 – 18:00 Approach to Spasticity Using Botulinum Toxin
Chair: Cindy Ivanhoe (Houston, TX, USA)
16:30 – 17:00 Management of Spasticity: Where Does BoNT Fit?
Nathaniel Mayer (Elkins Park, PA, USA)
17:00 – 17:30 Maximizing Outcomes in Spasticity Using BoNT
Cindy Ivanhoe (Houston, TX, USA)
17:30 – 18:00 Adjunctive Treatments for Spasticity
Joaquim Ferreira (Lisbon, Portugal)
Parallel Track – Clinical (Workshop A)
14:30 – 18:30 Treatment of Laryngeal Disorders and Oromandibular Dystonia
Chair: Andrew Blitzer (New York, NY, USA)
14:30 – 15:00 Evidence-Based Review: Abductor, Adductor, Vocal Tremor
Allen Hillel (Seattle, WA, USA)
15:00 – 15:30 Techniques for Injection Localization and Dosing
Andrew Blitzer (New York, NY, USA)
15:30 – 16:00 Oromandibular Dystonia
Raymond Rosales (Manila, Philippines)
16:00 – 16:30 Break
16:30 – 18:30 Demonstrations on Video and Live Patients
Miguel Coelho (Portugal)
Andrew Blitzer (New York, NY, USA)
Raymond Rosales (Manila, Philippines)
Allen Hillel (Seattle, WA, USA)
Parallel Track – Clinical (Workshop B)
14:30 – 18:30 Use of BoNT for Bladder Conditions
Chair: Michael Chancellor (Royal Oak, MI, USA)
14:30 – 15:00 Functional Anatomy of the Genitourinary Tract
Christopher Smith (Houston, TX, USA)
15:00 – 15:30 Introduction to Use of Botulinum Toxin for Genitourinary Conditions (Which Conditions, What Evidence?)
Michael Chancellor (Royal Oak, MI, USA)
15:30 – 16:00 Injection Techniques
Francisco Cruz (Barquinha, Portugal)
16:00 – 16:30 Break
16:30 – 18:30 Video and Pelvic Model Demonstrations
Michael Chancellor (Royal Oak, MI, USA)
Christopher Smith (Houston, TX, USA)
Francisco Cruz (Barquinha, Portugal)
Parallel Track – Clinical (Workshop C)
14:30 – 18:30 Cosmetic Uses of Botulinum Toxin
Chair:
Ellen Gendler (New York, NY, USA)
14:30 – 15:00 Introduction to the Anatomy of Facial Aesthetics
Jonathan Sykes (Sacramento, CA, USA)
15:00 – 15:30 BoNT Injections of the Face: Options and Outcomes
Ellen Gendler (New York, NY, USA)
15:30 – 16:00 BoNT Injections for Hyperhidrosis: Efficacy and Side Effects
Dee Anna Glaser (St. Louis, MO, USA)
16:00 – 16:30 Break
16:30 – 18:30 Demonstrations on Live Patients
João Maia Silva (Portugal)
Miguel Correia (Portugal)
Rui Oliveira Soares (Portugal)
Ellen Gendler (New York, NY, USA)
Dee Anna Glaser (St. Louis, MO, USA)
Jonathan Sykes (Sacramento, CA, USA)
Parallel Track – Clinical (Workshop D)
14:30 – 16:00 Techniques for Localizing Muscles for BoNT Injection: Demonstration Workshop
Chair: Erle Lim (Singapore)
14:30 – 15:00 EMG
Marina de Koning-Tijssen (Groningen, Netherlands)
15:00 – 15:30 Ultrasound
Katharine Alter (Bethesda, MD, USA)
15:30 – 16:00 Other Techniques, Including Inspection, Palpation, Anatomic Landmarks
Erle Lim (Singapore)
16:00 – 16:30 Break
16:30 – 18:00 Treatment of Tremor With BoNT
Chair: Dirk Dressler (Hannover, Germany)
16:30 – 17:00 Approach to Hand Tremors
Seth Pullman (New York, NY, USA)
17:00 – 17:30 Head Tremor
Wolfgang Jost (Wiesbaden, Germany)
17:30 – 18:00 Voice Tremor
Robert Bastian (Downers Grove, IL, USA)
Friday, January 16, 2015
07:00 – 18:30 Registration/Information
07:00 – 08:30 Exhibits
Plenary Session – The Botulinum Neurotoxins
Chairs: Cesare Montecucco (Padua, Italy) and Francisco Cardoso (Minas Gerais, Brazil)
08:30 – 09:10 Structure of the BoNT/A Receptor Complex
Richard A. Kammerer (Villigen PSI, Switzerland)
09:10 – 09:45 Differences in Mode of Action of the Different Toxins
Sabine Pellett (Madison, WI, USA)
9:45 – 10:20 Clinical Differences Between Type A and B Toxins
Anna Rita Bentivoglio (Rome, Italy)
10:20 – 10:50 Break
10:50 – 11:25 Clinical Differences Between A1 and A2 Botulinum Toxin Subtypes
Ryuji Kaji (Tokushima, Japan)
11:25 – 12:00 Ganglioside Trafficking and Antiganglioside Antibodies
Hugh Willison (Glasgow, UK)
12:00 – 13:45 Lunch
12:00 – 14:30 Exhibits
12:00 – 14:30 Poster Session
Participants will break up into separate groups for Basic Science, Clinical, Workshop A, Workshop B, Workshop C, and Workshop D sessions.
Parallel Track I (Basic Science)
14:30 – 16:00 Toxin Trafficking
Chair: Mauricio Montal (La Jolla, CA, USA)
 14:30 – 15:00 Multiple Domains of Tetanus Toxin Direct Entry into Primary Neurons
Joseph Barbieri (Milwaukee, WI, USA)
 15:00 – 15:30 Variations in VAMP1 Across Vertebrates Suggest a Potential Selective Pressure From Botulinum Neurotoxins
Min Dong (Southborough, MA, USA)
 15:30 – 16:00 The Long Duration of Action of Clostridium botulinum A5 Toxin at the Mammalian Neuromuscular Junction
M. Jordi Molgó (Paris, France)
16:00 – 16:30 Break
16:30 – 17:30 Immunity and Immunoprotection
Chair: Dorothea Sesardic (London, UK)
 16:30 – 17:00 Human Antibody Engineering for Prevention and Treatment of Botulinum Neurotoxin (BoNT) Intoxication
Jianlong Lou (San Francisco, CA, USA)
 17:00 – 17:30 VNAs as Unconventional and Versatile Therapeutics for Toxin-Mediated Diseases
Charles Shoemaker (Medford, MA, USA)
17:30 – 18:15 Toxin Detection
Chair:  Leonard Smith (Fort Detrick, MD, USA)
 17:30 – 18:00 Shining the Light on Botulism: Enzyme Acceleration, Fluorescent  and Bioluminescent Toxin Detection
Markus Kalkum (Duarte, CA, USA)
18:00 – 18:15 Broad-Spectrum Detection of All Clostridial Neurotoxins in Stem Cell-Derived Neurons and Identification of Compounds That Rescue Synaptic Activity in Synaptic Function-Based Assays
Patrick McNutt (Fallston, MD, USA)
Parallel Track I (Clinical)
14:30 – 16:00 Clinical Pearls: Optimizing Outcomes in Blepharospasm and Hemifacial Spasm
Chair: Giovanni DeFazio (Bari, Italy)
14:30 – 15:00 Diagnosis of Blepharospasm: Are We There Yet?
Giovanni DeFazio (Bari, Italy)
15:00 – 15:30 Is There One Toxin/Dose That is Superior to Another for Blepharospasm/Hemifacial Spasm (HFS)?
Anna Rita Bentivoglio (Rome, Italy)
15:30 – 16:00 How to Inject for Optimal Outcome
Earl Consky (Toronto, Canada)
16:00 – 16:30 Break
16:30 – 17:00 Platform Session − Long-Term Studies of BoNT Efficacy, Safety, and Responsiveness
Chairs: Giovanni DeFazio (Bari, Italy) and Peter Moore (Liverpool, UK)
 16:30 – 16:40 Treatment Patterns and Patient Disposition in the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE)
Cynthia Comella (Chicago, IL, USA)
 16:40 – 16:50 Efficacy of IncobotulinumtoxinA in Poststroke Upper Limb Spasticity: Results From a Large Multicenter 1-Year Noninterventional Study
Dirk Dressler (Hannover, Germany)
 16:50 – 17:00 Botulinum Toxin in Sialorrhea Is Safe and Effective in Long-Term Use
Martina Petracca (Rome, Italy)
17:00 – 18:30 Considerations When Botulinum Toxin Treatment Is Not Effective
Chair:
Peter Moore (Liverpool, UK)
17:00 – 17:30 The Many Causes of Secondary Nonresponse
Cynthia Comella (Chicago, IL, USA)
17:30 – 18:00 Molecular Basis of Immunogenicity to Botulinum Neurotoxins
M. Zouhair Atassi (Houston, TX, USA)
18:00 – 18:30 Assessing Antibodies to Botulinum Toxin
Dirk Dressler (Hannover, Germany)
Parallel Track II Clinical
14:30 – 16:00 Gait Lab: Functional Evaluation of Gait for Muscle Selection in Spasticity Patients
Chair: Alberto Esquenazi (Elkins Park, PA, USA)
14:30 – 15:00 A New Symptom-Based Approach to Neurological Gait Disorders
Alberto Esquenazi (Elkins Park, PA, USA)
15:00 – 15:30 Effects of Botulinum Toxin Treatment on Dystonic and Spastic Gait
Anja Van Campenhout (Pellenberg, Belgium)
15:30 – 16:00 Use of Gait Lab Studies in Lower Extremity Dystonia to Identify Muscles for Injection
Katharine Alter (Bethesda, MD, USA)
16:00 – 16:30 Break
16:30 – 17:00 Platform Presentations: Applications of Botulinum Toxin for Complicated Neurological Conditions:
Chair: Francisco Cardoso (Minas Gerais, Brazil)
16:30 – 16:40 Botulinum Toxin Type A (incobotulinumtoxinA) for Muscle Cramps Associated With Diabetic Neuropathy: A Double-Blind, Placebo-Controlled Study
Domenico Antonio Restivo (Catania, Italy)
16:40 – 16:50 OnabotulinumtoxinA Improves Pain in Poststroke Spasticity Patients: Findings from a Randomized Controlled Trial
Jörg Wissel (Berlin, Germany)
16:50 – 17:00 Efficacy and Safety Profile of IncobotulinumtoxinA in Children With Cerebral Palsy: Randomized Double-Blind Clinical Trial
Elena Carraro (Treviso, Italy)
17:00 – 18:30 Botulinum Toxin in Nondystonic Disorders
Chair: Francisco Cardoso (Minas Gerais, Brazil)
17:00 – 17:30 Botulinum Toxin for Hemiparetic Gait
Alberto Esquenazi (Elkins Park, PA, USA)
17:30 – 18:00 Tremor: Essential Tremor and Palatal Tremor
Hrishikesh Kumar (Kolkata, India)
18:00 – 18:30 Parkinson’s Disease – Clinical Aspects That Can Be Treated With Botulinum Toxin
Francisco Cardoso (Minas Gerais, Brazil)
Parallel Track (Workshop A)
14:30 – 18:30 Botulinum Toxin for Headache
Chair: Stephen Silberstein (Philadelphia, PA, USA)
14:30 – 15:00 Evidence-Based Review of BoNT for Headache
Alan Finkel (Chapel Hill, NC, USA)
15:00 – 15:30 Mechanism of Effect in Headache
Michael Oshinsky (Philadelphia, PA, USA)
15:30 – 16:00 Clinical Pearls for Optimal Outcome
Stephen Silberstein (Philadelphia, PA, USA)
16:00 – 16:30 Break
16:30 – 18:30 Case Studies: Injection Techniques for Headache
Live Patients and Models
Isabel Pavão Martins (Portugal)
Alan Finkel (Chapel Hill, NC, USA)
Michael Oshinsky (Philadelphia, PA, USA)
Stephen Silberstein (Philadelphia, PA, USA)
Parallel Track (Workshop B)
14:30 – 16:00 Controversies and Unresolved Issues in Use of BoNT
Chair: Daniel Truong (Fountain Valley, CA, USA)
14:30 – 15:00 Camptocormia
Carlo Colosimo (Rome, Italy)
15:00 – 15:30 Pain Other Than Headache
Bahman Jabbari (New Haven, CT, USA)
15:30 – 16:00 Anterocollis
Josef Finsterer (Vienna, Austria)
16:00 – 16:30 Break
16:30 – 17:00 Platform Session – Use of BoNT in Nondystonic Disorders
Chairs: Daniel Truong  (Fountain Valley, CA, USA) and Bernhard Voller (Vienna, Austria)
16:30 – 16:40 Consistent Long-Term Efficacy and Safety of Repeat OnabotulinumtoxinA Injections in Patients With Neurogenic Detrusor Overactivity: Final Results of Up to 4 Years’ Treatment
Karen Ethans (Winnipeg, Manitoba, Canada)
16:40 – 16:50 AbobotulinumtoxinA in the Treatment of Adults With Upper Limb Spasticity in a Randomized, Double-Blind, Placebo-Controlled Study  
Jean-Michel Gracies (Créteil, France)
16:50 – 17:00 An Exploratory, Single-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 16-Week Study of the Efficacy and Safety of Intra-Articular OnabotulinumtoxinA (OnabotA, 200 U) as Treatment for Osteoarthritis Knee Pain: Results from Experimental Pain Models
Lars Arendt-Nielsen (Jutland, Denmark)
Parallel Track (Workshop C)
14:30 – 18:30 Treatment of Focal, Task-Specific Dystonias
Chair: Charles Adler (Scottsdale, AZ, USA)
14:30 – 15:00 Musician’s Dystonia
Steven Frucht (New York, NY, USA)
15:00 – 15:30 Writer’s Cramp
Jennifer Goldman (Chicago, IL, USA)
15:30 – 16:00 Laryngeal Dystonia
Charles Adler (Scottsdale, AZ, USA)
16:00 – 16:30 Break
16:30 – 18:30 Video Demonstrations and Live Patients
Miguel Coelho (Portugal)
Steven Frucht (New York, NY, USA)
Jennifer Goldman (Chicago, IL, USA)
Charles Adler (Scottsdale, AZ, USA)
Parallel Track (Workshop D)
14:30 – 18:30 Practical Applications for Cervical Dystonia, Blepharospasm, and Spasticity – Video Demonstrations and Live Patient Injections
Chair:  Joaquim Ferreira (Lisbon, Portugal)
 
 
 
14:30 – 15:30
15:30 – 16:30
16:30 – 17:00
17:00 – 18:00
18:00 – 18:30
Spasticity
Allison Brashear (Winston-Salem, NC, USA)
Jorge Jacinto (Portugal)

Session I
Session II
Break
Session III
Q&A
 
 
 
14:30 – 15:30
15:30 – 16:30
16:30 – 17:00
17:00 – 18:00
18:00 – 18:30
Cervical Dystonia
Richard Barbano (Rochester, NY, USA)
Patrícia Lobo (Portugal)
Session I
Session II
Break
Session III
Q&A
 
 
 
14:30 – 15:30
15:30 – 16:30
16:30 – 17:00
17:00 – 18:00
18:00 – 18:30
Blepharospasm
Karen Frei (Loma Linda, CA, USA)
Anabela Valadas (Portugal)
Session I
Session II
Break
Session III
Q&A
Saturday, January 17, 2015
07:00 – 12:30 Registration/Information
07:00 – 09:00 Exhibits
Plenary Session – The Future
Chairs: Mark Hallett (Bethesda, MD, USA) and Andreas Rummel (Hannover, Germany)
08:15 – 9:00 INA Business Meeting
09:00 – 09:30 Depression
M. Axel Wollmer (Hamburg, Germany)
09:30 – 10:00 Pain, Sensory System, Central Effects
Peter Goadsby (San Francisco, CA, USA)
10:00 – 10:30 Shortened Intervals Between Injections
Hubert Fernandez (Cleveland, OH, USA)
10:30 – 11:00 Break
11:00 – 11:30 Gaps in Basic Knowledge
Cesare Montecucco (Padua, Italy)
11:30 – 12:00 Long-term Clinical Effects
Joseph Jankovic (Houston, TX, USA)
12:00 – 12:15 Closing Remarks
Joseph Jankovic (Houston, TX, USA)

Click here for the Lunchtime Symposia schedule.

Print this page.